Raptor Pharmaceutical Corp. Expands Senior Management

12-Sep-2012 - Raptor Pharmaceutical Corp. announced the appointment of Georgia Erbez, as Chief Financial Officer of Raptor, and Julie Anne Smith, as Executive Vice President, Strategy, and Chief Operating Officer. Ms. Erbez will be responsible for directing Raptor's global financial strategy and organization ...

Raptor Pharmaceutical Licenses Intellectual Property Related to Parkinson's Disease From Universite Laval

22-Jun-2012 - Raptor Pharmaceutical Corp. announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval.Raptor's agreement with Laval provides exclusive rights to technology ...

Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 in Non-Alcoholic Steatohepatitis

21-Dec-2011 - Raptor Pharmaceutical Corp. announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) part of the National Institutes of Health (NIH) to conduct a Phase 2b clinical trial. The clinical trial ...

Raptor Pharmaceutical Completes Enrollment in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis

25-Jan-2011 - Raptor Pharmaceutical Corp. announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis.The pivotal Phase 3 clinical trial is designed as an outpatient ...

Raptor Pharmaceutical Announces License Agreement for Convivia

01-Jul-2010 - Raptor Pharmaceutical Corp. announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. to commercialize Convivia(TM), Raptor's proprietary oral formulation of 4-methylpyrazole ("4-MP"), in Taiwan. Convivia(TM) is designed to reduce systemic acetaldehyde exposure and ...

Raptor Pharmaceutical Licenses Intellectual Property Related to Huntington's Disease

04-Jun-2010 - Raptor Pharmaceutical Corp. announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added ...

Raptor Pharmaceutical Announces Phase 2a NASH Study Meets Primary Endpoints

05-May-2010 - Raptor Pharmaceutical Corp. announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 5% to 11% of the U.S. ...

Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to Merge

Merger to Create NASDAQ-Listed Biopharmaceutical Company named Raptor Pharmaceutical Corp.

01-Oct-2009 - Raptor Pharmaceuticals Corp. announced that its stockholders approved the proposals to complete the proposed merger with TorreyPines Therapeutics, Inc. at its annual meeting of stockholders. Concurrently, at the annual meeting of its stockholders, TorreyPines stockholders approved all of the ...

Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease

Raptor to Support Phase 2a Clinical Trial at UCSD

21-Jul-2008 - Raptor Pharmaceuticals Corp. announced the execution of a collaboration agreement with the University of California, San Diego ("UCSD") to include a Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate in adolescents diagnosed with Non-Alcoholic ...

Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board

17-Jul-2008 - Raptor Pharmaceuticals Corp. announced the appointments of Richard L. Franklin, M.D., Ph.D. to the Company's board of directors and Stephen C. Blacklow, M.D., Ph.D. to its scientific advisory board. Dr. Franklin has 25 years of experience in the biomedical industry. He is currently Chairman of ...